Here’s Why 2 Major Health Centers Won’t Carry Controversial New Alzheimer’s Drug

July 16, 2021

Two of the nation’s most influential health systems have said they won’t administer Biogen’s Aduhelm, a controversial new Alzheimer’s treatment approved by the Food and Drug Administration last month, as concerns have grown about conflicting evidence about Aduhelm’s efficacy from clinical trials.

Read the source article at forbes.com
2021-07-15 01:00:00

Share This Story!